Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

Published:2008-07 Issue:7 Volume:99 Page:1492-1498
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Minami Hironobu,Kawada Kenji,Ebi Hiromichi,Kitagawa Koichi,Kim Yon-il,Araki Kazuhiro,Mukai Hirofumi,Tahara Makoto,Nakajima Hikaru,Nakajima Keiko

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2008.00837.x/fullpdf

Reference26 articles.

1. The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer

2. Targeting RAS signalling pathways in cancer therapy

3. The role of Raf kinases in malignant transformation

4. Cell signalling: growth factors and tyrosine kinase receptors

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients;Journal of Chromatography B;2024-04

2. Pharmacokinetics and apparent Michaelis constant for metabolite conversion of sorafenib in healthy and hepatocellular carcinoma-bearing rats;Bioanalysis;2024-03-26

3. The flavonoids from Pentorum chinense Pursh. mediates ferroptosis to alleviate sorafenib-induced liver injury in BRL-3A cells;TRADIT MED RES;2024

4. Enhancing phase I dose-finding trials design through dynamic borrowing information and handling late-onset toxicity;Frontiers in Pharmacology;2023-11-22

5. Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials;The Annals of Applied Statistics;2022-12-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3